Spyre Therapeutics, Inc.

SYRE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$208-$339-$84-$66
Dep. & Amort.$0$1$2$2
Deferred Tax$0$0-$0$0
Stock-Based Comp.$45$26$7$8
Change in WC-$5-$5-$6$2
Other Non-Cash$10$218$1$1
Operating Cash Flow-$157-$100-$80-$54
Investing Activities
PP&E Inv.$0$0-$0-$1
Net Acquisitions$0$3$0$0
Inv. Purchases-$599-$167-$40-$133
Inv. Sales/Matur.$246$40$97$111
Other Inv. Act.$0$15$0$0
Investing Cash Flow-$353-$108$57-$23
Financing Activities
Debt Repay.$0-$0-$0-$1
Stock Issued$236$169$43$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$175$192$0$2
Financing Cash Flow$411$361$43$1
Forex Effect-$0$0-$0-$0
Net Chg. in Cash-$100$153$19-$75
Supplemental Information
Beg. Cash$189$36$17$92
End Cash$89$189$36$17
Free Cash Flow-$157-$100-$80-$54
Spyre Therapeutics, Inc. (SYRE) Financial Statements & Key Stats | AlphaPilot